Drug Combo Shows Promise in Advanced Pancreatic Cancer

More than 70% of patients with pancreatic cancer derived a clinical benefit when treated in a small, phase I trial with the combination of nanoparticle albumin bound paclitaxel (Abraxane) and gemcitabine (Gemzar), investigators reported here.

Run time 2.39 mins

Tell Us What You Think

Do you have a review, update or anything you would like to add to this video content?

Leave your feedback
Submit
Nanotechnology Videos by Subject Matter